Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 11/20 | 0.69 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.69 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.69 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | NMBR | P28336 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9818653 | 0.95 | SOAT1 (0.73) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL9200734 | 0.95 | SOAT1 (0.77) | SOAT1SOAT2ACAT1NMBR | |
| Hydrochloric Acid SCHEMBL20591099 | 0.94 | SOAT1 (0.76) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL9641246 | 0.94 | SOAT1 (0.76) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL13328402 | 0.92 | SOAT1 (0.63) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL9640319 | 0.88 | SOAT1 (0.68) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL9818681 | 0.88 | SOAT1 (0.71) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL9641191 | 0.87 | SOAT1 (0.67) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL9640371 | 0.87 | SOAT1 (0.67) | SOAT1SOAT2ACAT1NMBR | |
| SCHEMBL9640381 | 0.86 | SOAT1 (0.66) | SOAT1SOAT2ACAT1NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-7615230-B2 | Topical applying N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide as ACAT inhibitor to treat oily skin; acylcoenzyme a cholesterol acyltransferase (ACAT) | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615230-B2 | Topical applying N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide as ACAT inhibitor to treat oily skin; acylcoenzyme a cholesterol acyltransferase (ACAT) | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-10 | — | — | US | disclosed |
| US-5015644-A | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds | WARNER-LAMBERT COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | SOAT1 17/4885SOAT2 28/4885ACAT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.